- Home
- MKTX vs SRRK Comparison
MKTX vs SRRK Comparison
Compare MKTX & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKTX | SRRK |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.5B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MKTX | SRRK |
|---|---|---|
| Price | $115.37 | $43.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $204.88 | $56.17 |
| AVG Volume (30 Days) | 611.1K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $397,471,000.00 | N/A |
| Revenue This Year | $10.14 | N/A |
| Revenue Next Year | $7.22 | $534.24 |
| P/E Ratio | $53.15 | ★ N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $115.55 | $27.07 |
| 52 Week High | $228.16 | $52.19 |
Technical Indicators
Market Signals| Indicator | MKTX | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 14.41 | 35.80 |
| Support Level | N/A | $42.52 |
| Resistance Level | $177.51 | $48.23 |
| Average True Range (ATR) | 3.90 | 1.99 |
| MACD | -0.99 | -0.65 |
| Stochastic Oscillator | 6.48 | 0.00 |
Price Performance
Historical ComparisonAbout MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.